MAIA Stock Summary and Trading Ideas (Maia Biotechnology | AMEX:MAIA)

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Maia Biotechnology trades on the AMEX stock market under the symbol MAIA.

As of September 18, 2026, MAIA stock price declined to $1.31 with 464,328 million shares trading.

MAIA has a beta of 2.60, meaning it tends to be more sensitive to market movements. MAIA has a correlation of 0.15 to the broad based SPY ETF.

MAIA has a market cap of $79.65 million. This is considered a Micro Cap stock.

In the last 3 years, MAIA traded as high as $5.99 and as low as $.82.

The top ETF exchange traded funds that MAIA belongs to (by Net Assets): VTI, VXF, IWC, BUSM.

MAIA has underperformed the market in the last year with a return of -16.6%, while the SPY ETF gained +16.8%. In the last 3 month period, MAIA fell short of the market, returning -6.4%, while SPY returned +2.3%. However, in the most recent 2 weeks MAIA has outperformed the stock market by returning -0.8%, while SPY returned -0.9%.

MAIA support price is $1.34 and resistance is $1.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MAIA shares will trade within this expected range on the day.